Search the Newsreel

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

Key Points The transaction involved the sale of 10,000 shares at $88.30 per share, resulting in a total value of $883,000 on July 15, 2026. The sale reduced the insider's total indirect equity holdings by 0.67%. These shares were held indirectly through the James …

BofA Securities Adjusts Price Target on Corteva to $96 From $90

BofA Securities has revised its price target for Corteva (NYSE: CTVA) shares, increasing it from $90 to $96. The firm maintains a Neutral rating on the agricultural science company's stock.

Is Profitability Improving Across Mission Produce's Segments?

Mission Produce faced profitability challenges in Q2 fiscal 2026 due to an unusual avocado pricing environment but expects improvement as supply normalizes, pricing stabilizes, and contributions from Peru and the Calavo acquisition strengthen its position. The Marketing & Distribution segment showed resilience despite headwinds, …

WCM Investment Management LLC Sells 92,666 Shares of Corteva, Inc. $CTVA

WCM Investment Management LLC reduced its stake in Corteva (NYSE:CTVA) by 1.1% in the first quarter, selling 92,666 shares but still holding a significant position. Despite the sale, institutional ownership of Corteva remains high at 81.54%. The company recently reported strong quarterly earnings, beating …

Swiss National Bank Boosts Holdings in Corteva, Inc. $CTVA

The Swiss National Bank increased its stake in Corteva, Inc. by 6.7% in the first quarter, bringing its total holdings to over 1.98 million shares valued at $166 million. Several other institutional investors also adjusted their positions in Corteva during the last quarter. Analysts …

KBC Group NV Purchases 771,480 Shares of Corteva, Inc. $CTVA

KBC Group NV has significantly increased its stake in Corteva, Inc. (NYSE:CTVA) by 58.8% in the first quarter, acquiring an additional 771,480 shares and bringing its total holding to over 2 million shares valued at approximately $174.4 million. This move highlights strong institutional interest, …

Hsbc Holdings PLC Has $106.09 Million Stock Position in Corteva, Inc. $CTVA

HSBC Holdings PLC reduced its stake in Corteva by 6.4% in the first quarter, now holding 1.27 million shares valued at approximately $106.1 million. Despite this, Corteva reported strong quarterly earnings, beating expectations with an EPS of $1.50 and revenue of $4.91 billion. Analysts …

Corteva, Inc. $CTVA Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp increased its stake in Corteva, Inc. (NYSE:CTVA) by 2.8% in the first quarter, now owning 0.70% of the company's stock valued at $394.93 million. Several other institutional investors also adjusted their positions in Corteva. The company has an …

Aware Super Pty Ltd as trustee of Aware Super Makes New Investment in Corteva, Inc. $CTVA

Aware Super Pty Ltd, as trustee of Aware Super, has initiated a new position in Corteva, Inc. (NYSE:CTVA) by acquiring 41,296 shares valued at approximately $3.46 million in the first quarter. Several other institutional investors also adjusted their holdings in Corteva during the same …

Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run Looms

Corcept Therapeutics(CORT.US) Officer Sells US$3.51 Million in Common Stock

Corcept Therapeutics (CORT.US) officer, Gary Charles Robb, sold 100,000 shares of common stock for a total of $3.51 million. The transaction took place on July 16, 2026, and the shares were sold at an average price of $35.1 per share. Following this sale, Robb …

Corcept Therapeutics director Wilson sells $882,985 in common stock

James N. Wilson, a director at Corcept Therapeutics Inc. (NASDAQ: CORT), sold 10,000 shares of the company's common stock for over $882,985 on July 15, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale occurs while the stock is near …

Corcept Therapeutics (CORT) CFO sells 40,000 shares and exercises options

Corcept Therapeutics CFO Atabak Mokari exercised options for 40,000 shares and subsequently sold all 40,000 shares on July 15, 2026. The sales were conducted under a Rule 10b5-1 trading plan and involved weighted average prices ranging from $86.7760 to $89.4282 per share. Following these …

ETFs Investing in Corteva Inc Stocks

This article lists various ETFs that invest in Corteva Inc (1CTVA) stocks, providing financial details such as market value, weight, issuer, expense ratio, AUM, price change, relative volume, and 3-year NAV total return for each fund. The funds range from broad market ETFs to …

Corcept Therapeutics (CORT) director logs 10,000-share indirect sale under 10b5-1 plan

Corcept Therapeutics director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, reported an indirect sale of 10,000 shares of common stock on July 15, 2026. The sales were executed under a Rule 10b5-1 trading plan at weighted-average prices ranging …

Responsive Playbooks and the CTVA Inflection

Corteva Inc. (NASDAQ: CTVA) is exhibiting neutral near-term sentiment but strong mid and long-term strength, characterized by a mid-channel oscillation pattern. The article identifies an exceptional 26.0:1 risk-reward short setup and outlines specific institutional trading strategies, including long, breakout, and risk-hedging plays, along with …

Corteva (NYSE:CTVA) Sets New 1-Year High - Time to Buy?

Corteva (NYSE:CTVA) recently reached a new 52-week high of $87.89, supported by positive analyst ratings and a consensus "Moderate Buy" rating with an average target of $88.95. The company also reported strong quarterly earnings, beating expectations with $1.50 EPS on $4.91 billion in revenue, …

Corteva stock hits all-time high at 87.75 USD

Corteva Inc. (CTVA) stock reached an all-time high of $87.75, with a strong year-to-date return of nearly 30% and a 1-year increase of 19.82%. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued. The agricultural giant is also preparing for a …

Corteva Highlights Transform Insecticide for Cotton Jassid Management

Corteva's Transform insecticide is being highlighted as an effective solution for managing cotton jassids, a new invasive pest in the southeastern U.S. University researchers and Corteva have collaborated on field trials, confirming Transform's efficacy against jassids, plant bugs, and aphids, while being less harmful …

Corteva Inc. stock underperforms Thursday when compared to competitors despite daily gains

Corteva Inc. stock (CTVA) gained 2.61% on Thursday, reaching $86.65, despite a general market downturn where the S&P 500 and Dow Jones Industrial Average both fell. However, the stock underperformed when compared to its unnamed competitors, even with its daily rise. This increase broke …

Corteva stands 2.3% from its high as Agricultural Inputs breadth sinks

The seed and crop-chemicals stock has separated from a weak Basic Materials cohort, but the latest week brought a pause, below-average volume and a still-negative activity-pressure read.

Kestra Advisory Services LLC Purchases 13,734 Shares of Corteva, Inc. $CTVA

Kestra Advisory Services LLC increased its stake in Corteva, Inc. by 19.8% in the first quarter, purchasing 13,734 shares to bring its total holdings to 83,060 shares valued at approximately $6.95 million. Corteva recently reported strong quarterly results, with earnings per share of $1.50 …

Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors

Earnings call transcript: Corcept Therapeutics Q1 2026 raises guidance amid Lifyorli launch

Corcept Therapeutics (CORT) Margin Compression Reinforces Bearish Narrative Despite FY 2025 Revenue Strength

Cortina’s H1 profit rises 10% to S$30.5 million amid stronger regional sales

Cortina Holdings profit up 4% YoY to $63.6m in FY2025

Cortina Holdings reports higher earnings of $63.6 mil for FY2025 up 4% y-o-y

Cortina Holdings reports 1HFY2025 profit after tax of $31.1 mil, down 8.6% y-o-y

Cortina Holdings announces several appointments following acquisition of Sincere Watch